Spebrutinib 10 mg | 97.14%
TargetMol
Spebrutinib is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
More Information Supplier PageSpebrutinib
Search Results
Spebrutinib 50 mg | 97.14%
TargetMol
Spebrutinib is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
More Information Supplier PageSpebrutinib
Spebrutinib 5 mg | 97.14%
TargetMol
Spebrutinib is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
More Information Supplier PageSpebrutinib
PIK-93 25 mg | 99.83%
TargetMol
PIK-93 is the first potent, synthetic PI4K inhibitor with IC50 of 19 nM; inhibits PI3Kα with IC50 of 39 nM.
More Information Supplier PagePIK-93
PIK-93 10 mg | 99.83%
TargetMol
PIK-93 is the first potent, synthetic PI4K inhibitor with IC50 of 19 nM; inhibits PI3Kα with IC50 of 39 nM.
More Information Supplier PagePIK-93
CEP-28122 5 mg | Purity Not Available
TargetMol
CEP-28122 is a highly potent and selective orally active ALK inhibitor.
More Information Supplier PageCEP-28122
CEP-28122 2 mg | Purity Not Available
TargetMol
CEP-28122 is a highly potent and selective orally active ALK inhibitor.
More Information Supplier PageCEP-28122
CEP-28122 25 mg | Purity Not Available
TargetMol
CEP-28122 is a highly potent and selective orally active ALK inhibitor.
More Information Supplier PageCEP-28122
CEP-28122 1 mg | Purity Not Available
TargetMol
CEP-28122 is a highly potent and selective orally active ALK inhibitor.
More Information Supplier PageCEP-28122
CEP-28122 10 mg | Purity Not Available
TargetMol
CEP-28122 is a highly potent and selective orally active ALK inhibitor.
More Information Supplier PageCEP-28122